efforts to cure HIV are hampered by limited characterization of the cells supporting HIV replication in vivo and inadequate methods for quantifying the latent viral reservoir in individuals receiving antiretroviral therapy (art). We describe a protocol for flow cytometric identification of viral reservoirs, based on concurrent detection of cellular HIV Gagpol mrna by in situ rna hybridization combined with antibody staining for the HIV Gag protein. By simultaneously detecting both HIV rna and protein, the cD4 t cells harboring translation-competent virus can be identified. the HIV rna/Gag method is 1,000-fold more sensitive than Gag protein staining alone, with a detection limit of 0.5-1 Gagpol mrna + /Gag protein + cells per million cD4 t cells. uniquely, the HIV rna/Gag assay also allows parallel phenotyping of viral reservoirs, including reactivated latent reservoirs in clinical samples. the assay takes 2 d, and requires antibody labeling for surface and intracellular markers, followed by mrna labeling and multiple signal amplification steps.
IntroDuctIon
In spite of the tremendous success of ART in controlling HIV replication and limiting progression to AIDS, current drug regimens do not lead to cure. No current scalable treatment can eradicate the virus from an HIV-infected person 1 or generate protective HIV-specific immunity 2 . The major barrier to HIV cure is the latent viral reservoir, a cell population primarily consisting of resting memory CD4 T lymphocytes that contain a stably integrated copy of the DNA provirus. HIV is able to rebound from this reservoir, usually within days or weeks, when a patient discontinues therapy; therefore, long-term adherence to ART is required. Although modern regimens are generally well tolerated, the longterm effects of ART remain unknown; individuals on suppressive ART remain at increased risk for a range of non-AIDS defining events 3, 4 . Therefore, the requirement for a life-long treatment, particularly in the context of limited access to ART and social stigma, remains a key issue driving the need for a cure.
Different strategies, alone or in combination, are currently under investigation to achieve an HIV cure 5 , such as preferential killing of viral reservoir cells; repopulation of the immune system by genetically engineered, infection-resistant cells; induction of deep latency; or generation of effective anti-HIV responses by therapeutic vaccines. A major strategy proposed for HIV cure is the 'shock and kill' 6 approach, whereby latency-reversing agents (LRAs) 'shock' the latent viral reservoir into reactivating. Cells containing reactivated HIV would either be killed by the pathogenic effects of the virus itself or targeted by the host's immune system, which may have to be vaccine-adjuvanted. Although this strategy has already been tested in limited clinical trials 7 , the relative ability of LRAs to induce different cellular reservoirs remains poorly understood. The latent HIV reservoir is formed early in acute infection 8, 9 and is inherently stable 10, 11 ; at present, no cellular markers have been identified that are capable of distinguishing the very rare CD4 T cells containing latent replication-competent proviruses (on the order of 1 per million resting CD4 T cells [12] [13] [14] [15] ) from uninfected, bystander cells. These factors have made both studying and targeting the latent viral reservoir for elimination highly challenging. The CD4 lineage presents tremendous heterogeneity in vivo, as do other cell types that might contribute to viral reservoirs (such as some myeloid cells 16 ). Regardless of the strategy pursued to achieve a HIV cure, a deeper understanding of the cells that support HIV replication in vivo and serve as longlived latent viral reservoirs in ART-treated subjects is required both to eliminate residual virus and to inform the development of a vaccine capable of eliminating HIV-infected cells.
Development of the protocol and comparisons with other methods
Research into HIV reservoirs has been limited by the sensitivity, specificity and caveats of available strategies used to detect and phenotype such cells. Standard techniques include, but are not limited to, the following: the use of in vitro cell lines and lab-adapted viruses to model infection; measurements of viral DNA by PCR for total or integrated viral genomes 13, 17, 18 ; and the quantitative viral outgrowth assay (QVOA) 12, 19 . Work performed using in vitro infections has provided a wealth of information, but is limited by the requirement of many models for cellular activation to enable efficient infection and/or the propagation of cells in vitro, both of which alter cell characteristics, and the substantial differences between lab-adapted viruses and the transmitted/ founder or chronic viruses circulating in the population. Not all integrated HIV proviruses are replication-competenti.e., able to produce fully infectious virus; indeed, over 90% of integrated HIV proviruses may contain deletions or mutations that preclude replication competence 20, 21 . Because of the prevalence and rapid accumulation of these defective/dysfunctional HIV genomes, PCR-based estimates represent the maximal viral
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reservoir size, even in individuals who initiated ART during acute infection 21, 22 . At the opposite end of the spectrum, the QVOA represents a minimal estimate, as not all replication-competent viruses are reactivated following a single round of stimulation 20 . Recent work has resulted in additional mRNA-based techniques, such as the Tat/Rev induced limiting dilution assay (TILDA) 23 , which have begun to close the gap between these two sets of measures. However, the above techniques rely either on population-level, rather than single-cell, analysis to detect viral reservoirs, resulting in a loss of critical information, or on limiting dilution strategy assays in which cell phenotypes cannot be determined retrospectively.
We thus sought to develop a flow-cytometry-based protocol for the single-cell identification and characterization of HIV viral reservoirs in primary samples from HIV-infected individuals 15 . Antibodies against HIV Gag proteins have been used previously to study in vitro infection, but are limited by high nonspecific binding, which prevents sensitive identification of HIV-infected cells at frequencies lower than 1,000 events per million 15 . By combining classic HIV Gag protein detection with RNA fluorescent in situ hybridization for HIV Gag and Pol mRNAs (mRNA Flow-FISH), we developed the HIV RNA/Gag assay, with which we are able to identify HIV RNA + /Gag + CD4 T cells in the range of 0.5-1 events per million. This gain in specificity markedly changes the scope of questions that can be addressed; it allows identification of HIV-infected CD4 T cells directly ex vivo in primary clinical samples from HIV-infected individuals, which was simply not possible with previous techniques.
To be identified by the HIV RNA/Gag assay, cells must contain virus that is able to transcribe viral mRNAs and translate viral protein. Therefore, we define this population as the translationcompetent reservoir in HIV-infected subjects with ongoing viral replication. In ART-treated, virally suppressed individuals, the assay identifies the translation-competent latent reservoir in cells following latency reversal. This assay effectively narrows the gap between the maximal and minimal estimates of the reservoir size mentioned above, although the characteristics of the reservoirs measured are distinct.
A key advantage and novel feature of the HIV RNA/Gag assay is that it enables concurrent phenotyping of both the HIV-infected CD4 T cells that are maintaining infection in viremic individuals and of the CD4 T cells, which reactivate the virus in response to LRAs, at a single-cell level. This type of information has previously been inferred only at a population level, for example, by sorting subsets of CD4 T cells and determining the relative reservoir size.
Limitations
Identification of latent HIV reservoirs in primary samples is limited by the rarity of these cells in ART-treated individuals (on the order of 1 per million resting CD4 T cells). We have observed that the application of the Poisson distribution to the detection of these rare events can be a key source of variability and dictates the starting number of cells required. In the hypothetical examples in Figure 1 , the true frequency of HIV RNA + /Gag + events is 2 per million CD4 T cells (the median size of the latent translationcompetent reservoir detected following phorbol myristate acetate (PMA)/ionomycin stimulation in our cohort 15 ). However, if 1 × 10 6 events are acquired on a flow cytometer, the probability of observing a frequency that differs by more than twofold from the true value (e.g., < 1 or > 4 HIV RNA + /Gag + events per million CD4 T cells) is 18.8% (Fig. 1a) . When 3 × 10 6 events are collected, the probability of detecting a frequency of HIV RNA + /Gag + events outside of this bracket falls to 7.1% (Fig 1b) , and at 10 × 10 6 events collected, it is 0.5% (Fig. 1c) . Thus, the more events acquired, the higher the accuracy of the assay. Although it is in principle possible to acquire 10 × 10 6 or more events by setting up several tubes per condition and merging the FACS data files, this is frequently impractical in terms of cell numbers, operating time and costs. Therefore, we routinely acquire between 2 and 4 × 10 6 CD4 T cells per subject, per condition.
To enable the collection of 2-4 × 10 6 CD4 T cells at the final step of acquisition on the flow cytometer, we begin with 100-200 × 10 6 peripheral blood mononuclear cells (PBMCs), depending on the individual's CD4 T-cell count and the number of conditions to be tested. We aim to put into culture, for each donor and condition, at least 15 × 10 6 CD4 T cells to take into account the cell loss associated with an overnight culture and the effects of the agents required for latency reversal. Following this culture, we then start each HIV RNA/Gag assay with 10 × 10 6 CD4 T cells to account for an observed ~70% cell loss throughout the protocol. This cell number requirement may be a substantial limitation for studies in which leukaphereses or large blood draws are not obtained. It should be noted that this requirement for high cell numbers is not specific to this assay but a reflection of the mathematical a Probability of acquiring observed frequency (%) 30 Probability <1: 13.5% Probability >4: 5.3% Poisson law. Thus, any other assay aiming at detection of very rare events, such as the QVOA, has similar requirements for high starting numbers of cells.
Where cell numbers are not limiting, we recommend that each user determine the number of events that must be analyzed on the basis of the expected frequency of their population of interest and taking into account Poisson distribution, as well as the expected losses indicated above.
The probe sets indicated here against HIV Gag and Pol ('Reagents') and used by our group 15 were designed against the Clade B isolate JR-CSF. Each probe set contains 20 individual probes, for a total of 40 when the probe sets against HIV Gag and Pol are combined; these recognize regions along the whole length of the target mRNA. This provides redundancy and tolerance for sequence variation, as not all probes need to bind to generate a signal. However, the more probes that bind, the brighter the signal (higher mean fluorescence intensity (MFI)). Therefore, when adapting the assay to detect alternative, shorter or more variable mRNAs, the number of probes may have a substantial impact on the sensitivity of the assay. In our North American cohorts, where the majority of individuals are infected with Clade B isolates, the redundancy in the HIV RNA/Gag assay has been sufficient to account for inter-donor variability. However, for studies on samples from outside of North America and Europe, we would recommend designing a probe set against the consensus sequence for the circulating clade.
As discussed previously, the HIV RNA/Gag assay narrows the gap between the maximal and minimal estimates of the reservoir size inferred by alternative methods. However, some caveats remain. As mentioned, the QVOA is limited to detection of latently infected cells that reactivate the virus upon a single round of stimulation, and therefore may underestimate the size of the latent reservoir 20 . As a similar stimulation technique is applied in the HIV RNA/Gag assay, the same applies here. Furthermore, it should be noted that the detection of a provirus by the HIV RNA/Gag assay does not guarantee that this virus is replication competent. Detection is dependent on the production of Gag protein and GagPol mRNA, defining a 'translation-competent reservoir'; however, a provirus with a deletion outside of GagPol would be detected with this assay but could be unable to initiate a productive infection. This translation-competent reservoir is likely to contain a lower proportion of defective proviruses (and thus a higher frequency of replication-competent proviruses) than alternative PCR-based measurements such as integrated HIV DNA and TILDA. However, it probably still represents an overestimate of the true replication-competent reservoir size.
Applications of the protocol
The version of the HIV RNA/Gag assay described 15 could be applied to questions involving the HIV replication cycle, restriction factor, viral pathogenesis or effectiveness of intervention/cure therapies. Regarding the HIV cure/latency field, the detection of the translationcompetent viral reservoir has substantial implications for (i) quantification of latent reservoir size; (ii) the efficacy assessment of cure strategies that rely on a reduction in the size of the latent reservoir, rather than complete eradication of latent proviruses; (iii) phenotyping of the viral reservoir; and (iv) the definition of HIV-infected CD4 cells as expressing HIV proteins, thus having the potential of being efficiently recognized by the adaptive immune system.
For the HIV RNA/Gag assay described here, we chose to use probes against both HIV Gag and Pol for the following reasons: (i) these regions have been shown to be relatively well conserved between clinical isolates; (ii) the length of these mRNAs allows for a relatively high number of mRNA-specific probes (40 total), which increases the redundancy in the system for intersubject sequence variability; and (iii) using a high number of probes amplifies the potential low copy number of HIV mRNAs per cell and increases the signal-to-noise ratio, thus increasing the detection limit in terms of RNA copy number. However, a key advantage of the HIV RNA/Gag technique is its versatility: it can easily be adapted to detect other HIV genes and proteins, including multiplexing different genes; flow panels can be adapted to quantify vast numbers of surface and intracellular markers-albeit with careful optimization; and-importantly-easy
Box 1 | Adaptation to a 96-well-plate format
The version of the protocol described here and validated extensively in our laboratory uses a 1.5-ml-tube version of the assay. However, the approach can be modified to a 96-well-plate format. We note that this version of the assay has not been validated by our group to the same extent as the tube-based protocol. The key steps are the same between assays. However, the plate-based assay is adapted to work with lower volumes and with a dry pellet (rather than a 100-µl residual volume). For example, in Step 33, samples should be resuspended at 10-50 × 10 6 per ml, such that plating 200 µl in each well of a v-bottom plate provides 2-10 × 10 6 cells per well. All wash steps should be performed with 200 µl per well; an additional wash is required to take into account any incomplete first washes (i.e., 100-µl wash for 100-µl residual volume) and pellets are resuspended in a fresh 100 µl of the appropriate buffer. When using an antibody stain, the dry pellets can be resuspended either in 100 µl of buffer (and then proceeding as though this is the residual volume) or in an antibody mix pre-prepared in 100 µl of the appropriate buffer. Spins are performed at 500g (1,000g after fixation) for 4 min at 4 °C or RT, depending on the step. Following spins, samples can be decanted by pipetting of the residual liquid or carefully flicking the plate. When deciding between the tube or plate versions of the assay, multiple factors must be considered. We have observed that cell loss may be greater, and more variable, when samples are processed in a plate as compared with tubes. Therefore, for precious samples, working with tubes may be preferable. There may also be sample transfer between adjacent wells; therefore, separation of samples on a plate is important to limit background. We have also observed that autofluorescent/nonspecific background in mRNA channels may be greater in plates as compared with tubes, which can negatively affect the signal/noise ratio. The major advantages of the platebased assay are operator ease of use and by extension an increase in the maximum number of samples that can be processed per day. The protocol is substantially shortened by the flicking of plates to wash, rather than aspiration of individual tubes. Given the potential advantages and disadvantages, we therefore strongly recommend that investigators compare the tube and plate protocols in parallel, in their laboratories and for their specific purposes, to determine the version best suited to their studies.
translation to other tissues/cell types (e.g., lymphoid tissues) and/or other species/viruses (e.g., SIV detection in rhesus macaques). This type of mRNA Flow-FISH assay can also be used to detect cytokines 24 , host factors and/or other pathogenrelated RNAs. Last, the assay could be transferred to alternative cell types; the protocol here focuses on the CD4 T-cell reservoir. However, cells of the myeloid lineage (including macrophages) have been proposed as important cellular reservoirs 25 and these subsets could in principle be investigated by the same technique, provided that the user undertakes careful validation of the protocol. Therefore, it represents a powerful tool that can be applied to address a broad range of experimental questions, both within the HIV field and in immunological studies in general.
The version of the HIV RNA/Gag assay described here focuses on the use of a commercially available RNA Flow-FISH assay (Human PrimeFlow, Affymetrix/eBioscience; see 'Reagents') to detect HIV reservoirs ex vivo. However, alternative Flow-FISH techniques have previously been used to identify HIV-infected alveolar macrophages 26 , study HIV-infected cell lines 27, 28 and detect HIV reservoirs in primary samples 29 . These methods use single-mRNA staining only and thus have limited specificity and accuracy. Therefore, the lessons learned from the development of this assay could easily be translated to an alternative product or an in-house system.
Biohazardous materials
Samples from human peripheral blood represent a Class 2 material; therefore, appropriate precautions should be taken according to institutional and governmental guidelines when handling these materials. HIV-1 is a Class 2 human pathogen, so samples from HIV-1-infected individuals should be handled in at least a Biosafety Level (BSL)-2 facility. In the culture conditions used for the standard experiment, a spreading infection is restricted by the presence of anti-retrovirals. However, we use BSL-3 guidelines when working with such samples. Appropriate personal protective equipment, including double gloves and eye protection are worn at all times. All solid waste is inactivated by autoclave incineration; all liquid waste is inactivated with Virkon or similar and autoclaved.
Experimental design
The protocol to detect HIV viral-translation-competent reservoirs can be broken down into two major parts. Sample preparation, Part I, is highly adaptable and can be extensively modified according to the experimental question. Part II comprises the specific steps of the HIV RNA/Gag assay; Part IIA describes protein antigen detection and Part IIB describes gene-specific mRNA detection. Although the core steps in Part II are constant, the assay can be adapted for detection of different protein antigens or mRNAs.
The procedure described here is for the identification of latent translation-competent reservoirs from HIV-infected, ART-treated individuals. In the example described in the PROCEDURE and associated tables, there are a total of 12 samples: samples from three different donors (one HIV-uninfected, two HIV-infected), each of which is tested after stimulation with an LRA at two different doses or after no stimulation, plus three control tubes in which in vitro-infected CD4 T cells may be used. As controls, we recommend the following: control A, an HIV-Gag protein fluorescent-minus-one (FMO); control B, an mRNA negative control using an irrelevant or scrambled mRNA probe; and control C, a positive-control mRNA. Controls A and B can be used to confirm the gating strategy defined using the HIV-uninfected biological control; control C is useful to determine whether the assay worked, in the absence of GagPol mRNA staining.
This protocol uses a 1.5-ml-tube-based version of the assay. The assay can also be performed in a 96-well-plate format; however, our group has not validated this version of the assay to the same extent as the tube-based protocol. We therefore recommend using the 1.5-ml-tube version for initial implementation and careful side-by-side comparison before the investigator considers switching to a 96-well-plate-based assay. See Box 1 for further discussion on the adaptation of the protocol to 96-well format.
Part I (4-6 h plus overnight incubation, fora standard experiment); sample preparation (Steps 1-24). Sample preparation is dependent on the experimental question to be addressed; however, in all cases the cells of interest must be in suspension to move into Part II (see Fig. 2 for example experiment setup). It is important to ensure that the cell preparation is of good quality, with high viability, if possible, to ensure reasonable cell recovery throughout the protocol. For detection of translation-competent reservoirs in HIV-infected individuals ex vivo, or following reactivation, we isolate CD4 T cells from freeze-thawed PBMC samples isolated previously. CD4 T cells are either rested or stimulated overnight with an LRA of interest. Samples from uninfected donors, treated in parallel, are used as biological controls and to determine the flow cytometry gating strategy. For identification of the translation-competent latent reservoir following treatment with LRAs in vitro, it is important to include a donor-matched, untreated condition. Additional relevant biological controls may be required depending on the experimental setup. See Box 2 for an ex vivo autologous infection protocol that can be used to prepare HIVpositive-control samples.
Part IIA (0.5 d); protein antigen detection (Steps 25-67).
Following stimulation/reactivation, CD4 T cells are collected, washed and divided into aliquots for staining (see Fig. 3 ). Samples are stained according to the experimental question with a mixture of surface antibody markers. As a minimum for primary cells, we recommend the inclusion of antibodies against basic phenotypic markers (CD3 and CD4) and an exclusion 'dump' channel (CD8, CD14, and CD19), as well as the addition of a viability dye to exclude dead cells and decrease background (see Table 1 for reagent setup for this panel and Table 2 for alternative panel options). Following fixation and permeabilization, samples are stained intracellularly for HIV-1 Gag protein as a minimum, but may also be stained for additional intracellular antigens concurrently. When staining for multiple markers, it is appropriate to include the same controls as for any multiparametric flow cytometry analysis, such as FMO controls. In FMO controls, the sample is stained for all markers (both mRNA and protein) except one and this is repeated for all markers. These controls can then be used to define the threshold of positivity when designing a gating strategy. Of note, for GagPol mRNA and Gag protein only, we recommend that gates be drawn using a biological control (e.g., an uninfected donor treated identically to the HIV-infected donors of interest) rather than FMOs. Following a second fixation, the protocol may be paused overnight. However, in general, for operator ease, we proceed to Part IIB and pause there at the second pause point. Transfer the 1 ml to a 15-ml conical tube. Repeat for all replicate wells. Wash out each well with 1 ml of warm R10 and combine with the CD4 T-cell suspension. Spin down the suspension (540g, 5 min, RT). 6. Wash the CD4 T cells twice in warm R10 to remove PHA. 7. Count cells using the method described in Step 6 of the main PROTOCOL. 8. Replate at 2 × 10 6 per ml in R20.
 crItIcal step As cell clumping due to activation may limit counting accuracy, we assume no cell loss over the incubation in step 4 and replate CD4 T cells in the starting volume from step 1. 9. Maintain cells for 6-7 d at ~2 × 10 6 per ml, by splitting 1:2 as required (with a maximum of every other day). Maintain IL-2 at 100 U/ml throughout the culture.
gene-specific mRNAs of interest, and then stored overnight; this is the second pause point (Fig. 4) . The following day, the signal is amplified using a branched dsDNA system and the amplified signal is labeled with a fluorescent dye. For detection of translation-competent reservoirs, we use probes designed against the GagPol region of the HIV-1 strain JR-CSF. Additional controls that may be included 30, 31 . Correct compensation controls are essential and are discussed in Box 3. A 1-laser machine can be used to detect the HIV-1 Gag protein and GagPol mRNA without additional antibody stains (see Table 2 for suggested panels/fluorochrome combinations), but this is not recommended for primary cells. 
MaterIals

REAGENTS
Peripheral CD4 T cells isolated from HIV-infected and uninfected donors
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Box 3 | Effective compensation
As with general flow cytometry experiments, the correct compensation is key to accurate interpretation of the results. For surface and intracellular antibodies, we recommend the use of eBioscience OneComp Beads. All beads are stained at the same time as the intracellular antibody stain to mimic as closely as possible any change in fluorochrome signal or stability over time. As fixation is known to alter fluorochromes, the antibody-stained beads are fixed for 1 h at RT with a solution of 2% paraformaldehyde, washed with 2% (vol/vol) FBS/PBS and then stored at 4 °C until use. There are two options for the compensation of the mRNA stain. The first is to use cells from the experiment stained only with a positive-control mRNA that is highly expressed by the cells of interest, such as RPL13A. This has the advantage that the autofluorescence and background is most similar to those of the cells of interest. However, we have found that the signal from the GagPol mRNA probe set is consistently brighter than that of the positive control, leading to compensation issues. Therefore, we stain BD CompBeads Plus with an isotype control antibody conjugated to the same fluorochrome as the mRNA (AF647 for Type 1, AF488 for Type 4 and AF750 for Type 6). It is key that the same fluorochrome is used for compensation as is used for the mRNA probe type-i.e., APC is not an appropriate substitute for AF647. These beads have a larger size than eBioscience OneComp beads and we have found that this provides more accurate compensation.
Label
Fluorescent label
Acquire on flow cytometer and analyze Figure 4 | Part IIB of the protocol. GagPol mRNA is labeled and amplified using a two-step dsDNA amplification system, and the amplified probe is labeled with a fluorescent marker. Samples can be stored short-term, or acquired by flow cytometry immediately, and then analyzed. OneComp eBeads (eBioscience, cat. no. 01-1111-42) Suggested antibodies, dyes and probes (see Table 2 
2|
Thaw required donor sample cryovials by warming them in a 37 °C water bath, until floating ice is visible. Transfer the contents of each vial to a cold 15-ml conical tube prepared in Step 1. Wash the cryovial with 1 ml of cold FBS and add the contents to the 15-ml conical tube. Add Nuclease S7 to each conical tube (20 µl per ml of PBMC suspension; minimum 40 µl), mix by tapping the tube and incubate for 20 s. Add cold FBS to a final volume of 10 ml.
3|
Centrifuge the conical tube at 420g for 10 min at 4 °C.
4|
Discard the supernatant and gently resuspend the pellet in 1 ml of cold R10 and top up to 10 ml with R10. If there are multiple conical tubes for a single donor, resuspend each of the pellets in 1 ml of cold R10 and combine in a single conical tube. Top this tube up to 10 ml with R10, and then split the sample back out into the starting number of conical tubes. Top all conical tubes up to 10 ml with R10. This will ensure that the PBMCs are split evenly across all conical tubes, and thus only one conical tube will need to be counted per donor, while keeping the number of cells per conical tube under 200 × 10 6 . Centrifuge the conical tubes at 420g for 10 min at 4 °C.
5|
Discard the supernatant and gently resuspend the pellet in 1 ml of cold EasySep CD4 isolation buffer and top up to 10 ml with EasySep CD4 isolation buffer.
 crItIcal step If you do not wish to isolate CD4 T cells-for example, for detection of HIV reservoirs in total PBMCs-perform
Step 5 in cold R10, count cells as in Steps 6 and 7, and then proceed to Step 19. The presence of CD8 T cells in a reactivated culture may have an adverse effect on the detection of the reactivated latent viral reservoirs; therefore, we recommend performing a CD8 depletion (for example, using Dynabeads CD8 Positive Isolation Kit; Thermo Fisher Scientific, cat. no. 11333D) as a minimum. 
6|
8| CD4 T-cell isolation.
Discard the supernatant and gently resuspend the pellet in EasySep CD4 isolation buffer at a volume of 20 µl per 10 6 cells (i.e., at 50 × 10 6 per ml). Remove any clumps of dead cells with a pipette.
9|
Transfer the cell suspension to a 14-ml FACS tube. PBMCs from multiple conical tubes from the same donor can be recombined into one 14-ml FACS tube. If total PBMC number is > 400 × 10 6 , prepare aliquots in multiple tubes. 
12|
Add EasySep CD4 isolation buffer to a final volume of 10 ml per 14-ml FACS tube.
13|
Transfer the 14-ml FACS tube to a 'Big Easy' StemCell isolation magnet. Remove the cap. Incubate for 5 min at RT.
14|
Prepare a fresh 15-ml conical tube with 2.5 ml of R10. Carefully pick up the magnet with the 14-ml FACS tube in place and slowly pour the unbound cell fraction into the fresh 15-ml conical tube containing R10. 
16|
Discard the supernatant and gently resuspend the pellet in 1 ml of cold R10 and top up to 10 ml with R10.
17| Count the isolated CD4 T cells as in Step 6.
? trouBlesHootInG 18| Centrifuge the conical tube at 540g for 5 min at 4 °C.
19| CD4 T-cell stimulation/reactivation of latent reservoirs.
Discard the supernatant and gently resuspend the pellet at 2 × 10 6 CD4 T cells/ml in R10 + antiretrovirals (Reagent Setup).
20|
Plate onto a sterile, 24-well, tissue-culture-treated plate at a volume of 1 ml per well.  crItIcal step Use only the middle 8 wells and fill the outer wells with 1 ml of sterile PBS at RT to limit loss by evaporation  crItIcal step The number of CD4 T cells per donor per condition is critical to the accurate detection of latent translation-competent reservoirs. For detection of very rare events (~1 per 10 6 ), we recommend starting with at least 16 × 10 6 cells-i.e., 8 wells at 2 × 10 6 per ml.
21|
Rest the cells at 37 °C with 5% CO 2 in a tissue culture incubator for 3 h.
22|
Prepare the LRAs as desired. For example, for PMA/ionomycin stimulation, use concentrations of 50 ng/ml and 0.5 µg/ml, respectively. For Bryostatin-1 use a concentration of 10 nM.  crItIcal step We recommend titrating these reagents to maximize cell activation and minimize toxicity in the time frame studied.
23| Add LRAs to each well for the appropriate final concentration. Mix by pipetting gently, or swirling the plate.
24|
Stimulate the cells overnight for 12-18 h at 37 °C with 5% CO 2 .  crItIcal step The optimal length of incubation is dependent on the LRA used and should be determined by the user.
part IIa: cell collection and preparation, viability staining, surface antibody staining and intracellular staining • tIMInG 4-11 h 25| Cell collection and preparation. As soon as incubation time ends, place all plates at 4 °C. Cool the centrifuge to 4 °C. Prepare cold 15-ml conical tubes for each donor/condition. We recommend checking the cultures under a microscope and taking note of any loss in viability and activation induced by any stimuli added.
26|
Collect the cells by pipetting gently up and down to mix with a 1-ml pipette. Transfer the cells to a 15-ml conical tube. Identical wells can be combined.
27|
Wash wells with cold R10. Add 1 ml to a well, pipette gently on the base of the well to lift any remaining cells and combine into 15-ml conical tubes. Repeat for all donors and conditions.  crItIcal step As soon as one 15-ml conical tube is full, place it at 4 °C to limit RNA degradation.
28|
Centrifuge the conical tubes at 540g for 5 min at 4 °C.
29|
Discard the supernatant and gently resuspend the pellet in 1 ml of cold R10 and top up to 10 ml with R10. Centrifuge the conical tubes at 540g for 5 min at 4 °C.
30|
Discard the supernatant and gently resuspend the pellet in 1 ml of cold 2% (vol/vol) FBS/PBS.
31| Count the isolated CD4 T cells as in
Step 6. In particular, take note of the cell viability. Samples with a low viability < 50-60% may produce high background and show poor cell recovery throughout the protocol. 
33|
Discard the supernatant and resuspend the pellets at 10 × 10 6 per ml in cold sterile PBS. Prepare 1-ml aliquots in PrimeFlow 1.5-ml low-binding RNase-free tubes for viability staining as described in Steps 36-40.  crItIcal step If no viability staining is required, resuspend in cold 2% (vol/vol) FBS/PBS, rather than PBS, follow Steps 34 and 35 and then proceed to Step 40 for surface staining. We recommend that a viability stain be used for all primary cell samples.
34| Centrifuge the tubes (600g, 5 min, 4 °C).
35| Remove 900 µl with a pipette, or using an aspirator. The line on the tube at 100 µl can be used as a guide. Resuspend the cells in the residual volume either by pipetting gently or vortexing on a low speed.  crItIcal step We have observed that vortexing, particularly for samples from HIV-infected, untreated individuals, has a negative impact on cell viability. We recommend that for fragile samples resuspension be performed carefully and by gentle pipetting. 43| Surface antibody stain. During the incubation, prepare a mix of titrated antibodies for the surface stain.  crItIcal step Antibody selection will affect the quality of the cell staining. See Box 4 for a detailed discussion.  crItIcal step Using the optimal antibody concentration to maximize the background/noise ratio is key. We advise titration of all antibodies used. As a minimum, we recommend antibody staining for basic phenotypic markers (e.g., CD3, CD4, exclusion) for cell identification.
36|
Box 4 | Antibody selection
As with general flow cytometry experiments, antibody selection (both in terms of the clone and fluorochrome) is critical to obtaining optimal results. First, with regard to monoclonal antibody selection, we have observed that some clones do not withstand the PrimeFlow procedure as well as others, resulting in a loss of signal. For example, the anti-CD4 clone RPA-T4 is more stable than SK3, but the latter can still be used. We recommend that each user test different clones against the antigen of interest before selection. Some fluorochromes are incompatible with the assay, including any peridinin chlorophyll protein (PerCP) or -Cy5 conjugates and Qdots. Signal from dim fluorochromes (such as V500 or FITC) may be masked by the increase in background associated with the assay. We have found that the BV dyes (BD, BioLegend) generally work well. However, we have observed degradation over time with some (BV650, in particular). Fluorochrome 'spreading' into other channels is also increased as compared with that observed in standard flow cytometry-for example, BV605 spreading into PE. These fluorochromes can be used, but only with careful antigen selection. We highly recommend the use of FMO (fluorescent minus one) controls to identify any potential issues. We have observed some limited interactions between specific BV dyes when multiple dyes are used in the same mix, as reported by BD Bioscience. This can be overcome by the addition of BD Horizon Brilliant Buffer (cat. no. 563794) to the antibody mix. We recommend that users determine the requirement of this buffer in their antibody panel of interest.
 crItIcal step If two or more Brilliant Violet (BV), Brilliant Ultra-violet (BUV) and Brilliant Blue (BB) fluorochromes are included in the panel, nonspecific interactions may be observed between these colors. Brilliant Stain Buffer (BD Bioscience, cat. no. 563794) can be used in preparation of the antibody mixes. We have not observed any issues when using this buffer with PrimeFlow; however, we highly recommend that investigators validate their specific antibody combinations with and without this buffer.
44|
Add surface antibody mix directly to the residual 100 µl. Mix well by pipetting.
45|
Incubate at 4 °C for 30 min in the dark.
46| Add 1 ml of cold 2% (vol/vol) FBS/PBS and invert the tubes three times to wash.
47| Centrifuge (600g, 5 min, 4 °C), discard the supernatant and resuspend the cells as in Steps 34 and 35, except here remove at least 1 ml to return to the 100-µl residual volume. This volume will now be used for all further steps. 
60|
If you are using additional intracellular antibody stains, add this mix directly to the residual 100-µl volume. If not, proceed to Step 61.
61|
Incubate for a further 30 min at 4 °C in the dark, so that the samples are stained with anti-Gag KC57 for a total of 1 h.  crItIcal step Anti-Gag KC57-RD-1 requires a longer staining time as compared with most intracellular stain (ICS) antibodies. We have found that staining with anti-Gag KC57-RD-1 for 30 min at RT, before staining with additional intracellular antibodies, is optimal to maximize the anti-Gag signal while minimizing background for additional intracellular antibodies.
62|
During this incubation, warm a 50-ml aliquot of Wash Buffer to RT. 66| Add 1 ml of RT Fixation Buffer II to the 100-µl residual volume and invert three times to mix.
67|
Incubate for 1 h at RT in the dark.  pause poInt As an alternative to this incubation, samples can be stored overnight in Fixation Buffer II at 4 °C. However, we have observed that longer-term storage in fixation buffers increases background and negatively affects fluorochrome stability. Therefore, we recommend continuing to a later Pause Point.
part IIB: labeling of mrna, amplification, labeling of amplified signal and data acquisition • tIMInG 1.5 d  crItIcal From this point forward, all buffers should be at RT or warmer; reagents and steps should be carried out at RT or above.
68| Labeling mRNA. During the incubation in
Step 67, thaw mRNA target probes at RT and prepare mRNA Target Probe Mixes in Target Diluent. See table 1 for example calculations. Mixes should be warmed to 40 °C before use.  crItIcal step mRNA Target Probe Mix preparation is critical. The target probes should be added directly to the appropriate volume of Target Diluent; do not pipette down the sides. Mixes should be well-mixed by pipetting. The liquids are viscous and difficult to work with. We recommend using low-binding RNase-free tips where possible and preparing additional reagent to take into account pipetting error. The number of additional tests that we routinely prepare for is shown in table 3.  crItIcal step PrimeFlow probes are available in three colors (types): Types 1 (AF647), 4 (AF488) and 6 (AF750). Types 1 and 4 are recommended for low-copy-number RNAs or RNAs for which the expression level is not known. Antibodies and mRNA probes cannot be used on fluorochromes with overlapping spectra (i.e., a FITC-tagged antibody cannot be used with a Type 4 AF488 probe set). 74| Add 100 µl of the warm Target Probe Mix directly to the 100-µl residual volume; do not add down the sides of the tubes. Mix gently by pipetting until the two liquids no longer appear separate. Vortex briefly to mix, with two pulses on a low speed. Where possible, work in the dark.  crItIcal step Ensure that the cell pellets are well resuspended in the residual 100 µl before addition of the Target Probe Mix.
75|
Place the samples into a metal heat block within an oven preheated to 40 °C.
76|
Incubate for 1 h at 40 °C.  crItIcal step The correct temperature is very important. We recommend monitoring the temperature at all times. It should be 40 °C; a tolerance of ±1 °C is acceptable. The oven used should be well calibrated and the temperature stable.
77|
Remove the metal heat block containing the tubes from the oven. Invert the whole heat block to mix, taking care to hold the tubes in place.
78|
Incubate for a further 1 h at 40 °C. After overnight storage at 4 °C, warm samples to RT and pipette or gently vortex to resuspend pellets in the residual 100-µl volume before proceeding. Also warm the Wash Buffer required for Step 87 to RT.
79|
82| Amplification.
Transfer the required volume of preamplification mix to a 1.5-ml RNase-free tube. Place in the heat block and warm to 40 °C.
83|
Add 100 µl of the warm preamplification mix directly to the 100-µl residual volume; do not add down the sides of the tubes. Mix gently by pipetting until the two liquids no longer appear separate. Vortex briefly to mix, with two pulses on a low speed. Where possible, work in the dark.  crItIcal step Ensure that the cell pellets are well resuspended in the residual 100 µl and at RT before addition of the preamplification mix.
84|
85| Incubate for 1.5 h at 40 °C.
86|
Add the required volume of amplification mix to a 1.5-ml RNase-free tube. Place the tube in the heat block and warm to 40 °C.
87| Add 1 ml of RT Wash Buffer to the 200-µl residual volume. Invert three times to mix.
88| Centrifuge (800g, 5 min, RT), discard the supernatant and resuspend as in Steps 69 and 70.
89|
Repeat Steps 87 and 88 twice, so that the samples are washed three times.
90|
Add 100 µl of the warm amplification mix directly to the 100-µl residual volume; do not add down the sides of the tubes. Mix gently by pipetting until the two liquids no longer appear separate. Vortex briefly to mix, with two pulses on a low speed. Where possible, work in the dark.  crItIcal step Ensure that the flow cytometer is clean before use; false-positive events will affect the limit of detection of the assay.  crItIcal step We recommend running samples slowly to decrease the electronic abort rate. In our experience, diluting samples to ~2,000 events per second and running at the lowest speed setting on a BD LSRII allows for maximal cell and event recovery.  crItIcal step Collecting a large number of events (2-4 million) takes up considerable memory and may cause issues with acquisition software; therefore, we recommend collecting data only within the 'Lymphocyte' or P1 gate to minimize data usage.
? trouBlesHootInG Figure 5a . RPL13A is stained with a Type 1 (AF647) probe here. As shown in the histogram, a majority of the cell population is clearly identified as positive for this mRNA. Example GagPol mRNA staining is shown in Figure 5b ,c. Here, CD4 T cells from an HIV-uninfected negative-control donor (UC, Fig.  5b ) or an HIV-infected donor (HIV + , Fig. 5c Example GagPol mRNA and Gag protein staining of CD4 T cells for a UC, HIV-infected, untreated, chronic progressing (CP) individuals and two HIV-infected, ART-treated participants (ART-T) is shown in Figure 6 . Samples were gated as in supplementary Figure 1 , except that no gating was performed based on CD3, as this marker was downregulated with stimulation. The false-positive rate observed in UC is exceptionally low. We observed a total of 3 false-positive HIV RNA + /Gag + cells from a total of 30.5 × 10 6 UC donor CD4 T cells tested-an average of 0.1 false-positive HIV RNA + /Gag + events per 10 6 cells. The frequencies detected in HIV-infected primary samples vary considerably, depending on participant factors, including viral load and ART, as well as the stimulation used 15 . In samples from CP individuals, we readily detected HIV RNA + /Gag + CD4 T cells Box 5 | Sorting of HIV RNA/Gag assay samples for microscopy • tIMInG 3.5 d HIV mRNA and protein can be visualized in CD4 T cells from HIV-infected subjects by microscopy using the HIV RNA/Gag assay. In our case, isolated CD4 T cells infected with autologous virus after an ex vivo expansion for 7 d were used as in Box 2. This box continues from Step 102 of the main PROCEDURE. Process samples as described in the complete, detailed protocol. Samples should be stained with a minimal panel such as Panel B of table 2, except that staining for CD3 and CD4 is not required. additional reagents/equipment poly-l-lysine (0.01%, Sigma-Aldrich. cat. no. P8920) DAPI (Sigma-Aldrich, cat. no. D9542) µ-Slide VI 0.4 slides (Ibidi, cat. no. 80601) procedure The marked gain in specificity with the HIV RNA/Gag assay as compared with standard flow-cytometry-based methods is due to the simultaneous detection of HIV mRNAs and proteins. As illustrated in Figure 7 , high background staining is observed in the representative HIV-UC when analysis is performed using HIV Gag protein or GagPol mRNA staining alone (Fig. 7a,b) . This background is sufficient to effectively mask the signal from two HIV-infected, untreated CP individuals, in particular for CP individual 2, who has a low viral load ( < 10,000 copies per ml). However, dual staining for both Gag protein and GagPol mRNA results in a decrease in background for the UC (0 events detected in 2 × 10 6 CD4 for this UC) and enables identification of rare HIV RNA + /Gag + CD4 T cells in both CP individuals at very low frequencies (13 per million for CP individual 2, Fig. 7c,d) .
A major advantage of the HIV RNA/Gag assay is that it can be used to characterize and phenotype HIV reservoirs on a single-cell level. In Figure 8 , example flow cytometry plots are shown for samples from an ART-T individual, in which isolated CD4 T cells were stimulated with the LRA Bryostatin-1 (10 nM, 18 h) and stained as in Panel C of table 2. CD4 T cells were gated first as in supplementary Figure 1 , except that no gating was performed based on CD3, as this marker was downregulated with stimulation. HIV RNA + /Gag + events were then gated as in Figure 8a . These HIV RNA + /Gag + events, which represent the bryostatin-reactivated translation-competent reservoir, can then be analyzed for expression of additional phenotypic markers such as CD45RA and CD27, shown in Figure 8b as compared with the total CD4 phenotype.
Samples that have been processed with the HIV RNA/Gag assay can be used in downstream applications, including FACS and microscopy. This technique can be used to identify and sort very rare populations of cells, enabling microscopy analysis of a pure population of interest. Example images from HIV-infected CD4 T cells processed as in Box 5, and sorted and analyzed by microscopy are shown in Figure 9 . 
